US 12,760,365 B2 · Clinical and molecular prognostic markers for liver transplantation

Abstract

The invention relates to a method for predicting the outcome of a liver transplantation for treatment of hepatocellular carcinoma (HCC), or to a for assigning a HCC patient to receive liver transplantation, comprising the step of determining the expression level of an indicator gene selected from dermatopontin, clusterin, calpain small subunit 1, F-box and WD repeat containing protein 7 and Sprouty RTK signalling antagonist 2 in a liver sample obtained from a patient suffering from HCC, and comparing the indicator gene expression level to the expression level of an internal control gene, which combined with the variable Total Tumor Volume using a linear support vector machine algorithm predicts positive prognosis of liver transplant recipients.

Claims10

Dependent claims

A method for treating hepatocellular carcinoma (HCC) in a patient, comprising:

determining whether a patient previously diagnosed with HCC is likely to have an increased chance of disease-free survival (DFS) at 5 and 10 years following liver transplantation, by:
detecting, in a liver sample obtained from the patient, overexpression of each gene of a group of indicator genes comprising clusterin (CLU) and dermatopontin (DPT);
wherein overexpression of both genes of the group of indicator genes indicates that the patient will have a greater chance of disease-free survival (DFS) at 5 and 10 years following liver transplantation than a patient in which only one of CLU or DPT is overexpressed;
and
performing liver transplantation on the patient determined to have an increased chance of DFS at 5 and 10 years.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application

17/712,201Filed 4 Apr 2022 · continuation in part

Priority

EP 192012182 Oct 2019

Published

US 2022/0228218 A121 Jul 2022

Granted

13 Oct 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification4 codes

C12Q 1/6883
Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes: for diseases caused by alterations of genetic material
C12Q 2600/118
Oligonucleotides characterized by their use: prognosis of disease development
C12Q 2600/158
Oligonucleotides characterized by their use: expression markers
C12Q
Measuring or testing processes involving enzymes, nucleic acids or microorganisms

Clinical and molecular prognostic markers for liver transplantation

Life of this patent

Clinical and molecular prognostic markers for liver transplantation

Life of this patent

Abstract

Claims10